Reduced serum paraoxonase 1 (PON1) activity in patients with schizophrenia treated with olanzapine but not quetiapine

Creative Commons License

Unsal C., Albayrak Y., Albayrak N., Kuloglu M., Hashimoto K.

NEUROPSYCHIATRIC DISEASE AND TREATMENT, cilt.9, ss.1545-1552, 2013 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 9
  • Basım Tarihi: 2013
  • Doi Numarası: 10.2147/ndt.s52463
  • Dergi Adı: NEUROPSYCHIATRIC DISEASE AND TREATMENT
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1545-1552
  • Anahtar Kelimeler: second generation antipsychotics, SGA, atherosclerosis, metabolic, dyslipidemia, LDL-C, HEART-DISEASE RISK, ATYPICAL ANTIPSYCHOTICS, TRIGLYCERIDE LEVELS, WEIGHT-GAIN, LIPID-LEVELS, GENE PON1, ARYLESTERASE, RISPERIDONE, DRUGS, HYPERLIPIDEMIA
  • Akdeniz Üniversitesi Adresli: Hayır

Özet

Background: Second generation antipsychotics (SGAs) are currently the most prescribed drugs in the treatment of schizophrenia. Despite their advantages, which include greater improvement in negative symptoms, cognitive function, prevention of deterioration, quality of life, and fewer extrapyramidal symptoms, the concern regarding metabolic abnormalities which might cause cardiovascular diseases during treatment with SGAs have been rising. Paraoxonase 1 (PON1) is an enzyme mostly located on high-density lipoprotein particles, and has been shown to protect or inhibit lipoprotein oxidation. Growing evidence suggests that PON1 plays a key role in the pathophysiology of atherosclerosis.